This inventor holds 2 USPTO granted patents and 7 published patent applications and 1 EPO patent. Top assignees: Gflas Life Sciences, Inc., Seoul National University. Active years: 2022-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 4 
1 out of 1,789 
Years Active: 2022-2024
Title: Mi Jin Park: Innovator in Cancer Treatment
Introduction
Mi Jin Park is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer treatment through his innovative pharmaceutical compositions. With a total of 2 patents, Park is dedicated to advancing medical science and improving patient outcomes.
Latest Patents
Park's latest patents include a pharmaceutical composition for treating cancer, which contains guide RNA and endonuclease as active ingredients. This composition can be customized according to the needs of patients or specific cell types, allowing for targeted treatment of cancer cells based on the unique binding properties of DNA and RNA. The CRISPR PLUS system, which includes both an endonuclease and an exonuclease, enhances the specificity of cancer treatment by activating nuclease activity through the binding of crRNA to genes found specifically in cancer cells. This results in a more effective treatment compared to traditional anti-cancer agents.
Another notable patent focuses on sequence-specific in vivo cell targeting. This invention involves enhanced nucleic acid targeting complexes that comprise endo and exonuclease activity. The related methods allow for the targeted degradation of specific and non-specific nucleic acids in vivo, as well as the temporal regulation of nuclease activity to prevent off-target effects. This innovation enables the selective degradation of nucleic acids and cells harboring them, such as cancer cells or pathogens, in a living organism.
Career Highlights
Throughout his career, Mi Jin Park has worked with notable organizations, including Gflas Life Sciences, Inc. and Seoul National University. His work in these institutions has furthered his research and development in the field of cancer treatment.
Collaborations
Park has collaborated with esteemed colleagues, including Jung Hak Lim and Sungyong In, who have contributed to his research endeavors.
Conclusion
Mi Jin Park is a trailblazer in the field of cancer treatment, with innovative patents that hold the potential to revolutionize patient care. His dedication to research and collaboration underscores his commitment to advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile